Mike Hennessy

The first and thus far only PARP inhibitor to gain regulatory approval, olaparib traveled a tortuous path to the 2014 FDA ruling that enabled its use for women with recurrent ovarian cancer.

The gold standard for patients with cancer has long been overall survival, preferably delivered up with statistical significance through a randomized, phase III clinical trial.

One group of oncologists has found a way to generate more business while at the same time addressing the unwillingness of people to come for screening.

Technology is in the works that would allow medically useful personal health metrics to be collected by sensors that can be incorporated into clothing, accessories, or skin patches, and then transmitted electronically for analysi

During our many years in the oncology information field, we’ve continually been impressed and inspired by the talent, dedication, and caring nature of the researchers and clinicians who treat patients with this most complex set of diseases.

Although many reform efforts are based on good intentions, these efforts are not always well respected. There is a drive afoot to terminate the charter for the Center for Medicare & Medicaid Innovation.

There are important ethical questions that must be fully considered when scientific research of any kind is conducted.

Tens of millions of medical profiles have been hacked from payers and oncology practices in just the past few years.

The past 5 years have been a whirlwind of fresh developments in the field of anticancer immunotherapies, and there is certainly no doubt that we have entered a new era of oncology care.

Even under the best of circumstances, the CRISPR gene-editing technology that we explore in this issue of OncologyLive won’t make it into clinical practice any time soon.

The right technology can make a wonderful difference, but what if everybody has it? Such is the case with patient assistance-funding software, the use of which is now becoming widespread.

As summer comes to a close, I want to turn your attention to the upcoming 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®, which takes place in New York City, November 9-11, 2016.

There’s no question that checkpoint blockade immunotherapy agents, most notably those directed at the PD-1/PD-L1 pathway, will continue to grow in importance as an anticancer modality in a rising number of tumor types.

Although it is gratifying to take stock of the many advances that have been made in the oncology field in recent years, it remains vitally important that we keep in mind just how much work there remains to be done.

The Oncology Care Model blew into town this month, rattling the shutters and bringing with it a lot of dust.

During the annual American Urological Association meeting leaders in urology presented groundbreaking research, new clinical guidelines, and the latest advances in urologic medicine.

Sometimes it seems as though we’ve become addicted to a big story mentality when it comes to the American Society of Clinical Oncology Annual Meeting.

As we approach the 1-year anniversary of Contemporary Radiation Oncology (CRO) publication, it occurs to me, upon reflection, how much change has occurred in the utilization of radiation oncology for cancer treatment in recent months.

Turning around any ship of state, particularly one as large and unwieldy as the oncology research establishment, is always going to be a slow-moving and laborious undertaking.

The saying on Wall Street is "sell in May and go away," but there's no detaching from the cliffhanger that CMS has left in the air.

Value-based care is becoming a new catch phrase in American medicine, especially in the oncology arena.

A not-so-subtle change in the physician drug payment scheme from The Centers for Medicare & Medicaid Services could be the proverbial straw that broke the camel’s back.

The cascade of news about cancer research—whether it’s about a new drug, biomarker, or treatment approach—has become an ever-present feature of the oncology landscape

We’re talking about a certain type of “more”— more intervention earlier and more effectively in the natural history of a malignancy in order to prevent a recurring or metastatic manifestation of a cancer.

The ongoing value transition got a bit more real in March when The Centers for Medicare & Medicaid Services introduced a proposal for Medicare Part B drug payment changes that would even out the margins that physicians make on drug sales.

With new therapies in prostate, kidney, and bladder cancer on the horizon and tightening regulatory and reimbursement restrictions in place, urologists need to adapt to a quickly changing landscape.

There are many reasons why we should change the way we approach cancer research and evaluate potential new drugs.

Today, there are multiple choices of regimens in two different modalities that can either prolong survival or allow patients to live without disease progression or recurrence for several years.

In this month’s issue of Oncology Business Management, we take you to Hawaii and Alaska to peel back the curtains on how oncologists in remote corners of the United States have innovated to keep their businesses vibrant and effective.

The creation of new technology is a complicated, risky business regardless of the area of healthcare or industry. The cover story in this issue, “Proton Beam Centers Multiply Despite Economic Risks,” illustrates that the oncology field is no exception to those rules of the marketplace.